AU2001246477A1 - Farnesyl protein transferase inhibitor combinations with platinum compounds - Google Patents

Farnesyl protein transferase inhibitor combinations with platinum compounds

Info

Publication number
AU2001246477A1
AU2001246477A1 AU2001246477A AU4647701A AU2001246477A1 AU 2001246477 A1 AU2001246477 A1 AU 2001246477A1 AU 2001246477 A AU2001246477 A AU 2001246477A AU 4647701 A AU4647701 A AU 4647701A AU 2001246477 A1 AU2001246477 A1 AU 2001246477A1
Authority
AU
Australia
Prior art keywords
protein transferase
platinum compounds
transferase inhibitor
farnesyl protein
inhibitor combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001246477A
Inventor
Ivan David Horak
Peter Albert Palmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2001246477A1 publication Critical patent/AU2001246477A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001246477A 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with platinum compounds Abandoned AU2001246477A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00200690 2000-02-29
EP00200690 2000-02-29
PCT/EP2001/002160 WO2001064226A2 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with platinum compounds

Publications (1)

Publication Number Publication Date
AU2001246477A1 true AU2001246477A1 (en) 2001-09-12

Family

ID=8171109

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001246477A Abandoned AU2001246477A1 (en) 2000-02-29 2001-02-26 Farnesyl protein transferase inhibitor combinations with platinum compounds

Country Status (6)

Country Link
US (1) US20030027808A1 (en)
EP (1) EP1261356A2 (en)
JP (1) JP2003525246A (en)
AU (1) AU2001246477A1 (en)
CA (1) CA2397657A1 (en)
WO (1) WO2001064226A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
CA2547518A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
CA2559282A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital Methods for the treatment of synucleinopathies
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
WO2007075923A2 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
EP2178893A4 (en) * 2007-07-16 2012-09-19 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
AU2009210654A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
BRPI0920927A2 (en) * 2008-11-13 2019-09-24 Link Medicine Corp azaquinolinone derivatives and uses thereof
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US9303015B2 (en) 2012-10-16 2016-04-05 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORγt
ES2628365T3 (en) 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Phenyl-linked quinolinyl modulators of ROR-GAMA-T
MX358508B (en) 2012-10-16 2018-08-22 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t.
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
CA2927182A1 (en) 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Quinolinyl modulators of ror.gamma.t
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
EP3057421B1 (en) 2013-10-15 2019-11-20 Janssen Pharmaceutica NV Alkyl linked quinolinyl modulators of ror(gamma)t

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (en) * 1995-12-08 2002-12-12 Janssen Pharmaceutica Nv (IMIDAZOL-5-YL) METHYL-2-CHINOLINO DERIVATIVES AS A FARNESYL PROTEIN TRANSFERASE INHIBITOR
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
PL190944B1 (en) * 1997-04-25 2006-02-28 Janssen Pharmaceutica Nv A derivative of quinazolinone and method for its manufacture as well as pharmaceutical compound and method for its manufacture
US6387903B1 (en) * 1997-08-27 2002-05-14 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
HUP0102473A3 (en) * 1997-12-22 2003-07-28 Schering Corp Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
EP1087770A4 (en) * 1998-06-15 2001-11-14 Merck & Co Inc Inhibitors of prenyl-protein transferase
AU760027B2 (en) * 1998-07-02 2003-05-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6329376B1 (en) * 1998-10-29 2001-12-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE69907964T2 (en) * 1998-12-23 2004-02-19 Janssen Pharmaceutica N.V. 1,2-FELLENED CHINOLINE DERIVATIVES
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression

Also Published As

Publication number Publication date
CA2397657A1 (en) 2001-09-07
WO2001064226A3 (en) 2002-03-07
EP1261356A2 (en) 2002-12-04
US20030027808A1 (en) 2003-02-06
JP2003525246A (en) 2003-08-26
WO2001064226A2 (en) 2001-09-07

Similar Documents

Publication Publication Date Title
AU2001246477A1 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2001240658A1 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
AU2001254672A1 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
AU2001234484A1 (en) Amide compounds for inhibiting protein kinases
AU2001258771A1 (en) -secretase inhibitors
NO20011356D0 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU2001235496A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
AU2001252147A1 (en) Farnesyl protein transferase inhibitor combinations
AU2001244166A1 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
AU2001246478A1 (en) Farnesyl protein transferase inhibitor combinations with taxane compounds
ATE293622T1 (en) FARNESYL PROTEIN TRANSFERASE INHIBITORS
AU2001239275A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
AU2001230336A1 (en) Fixture
AU2001247882A1 (en) Tricyclic protein kinase inhibitors
AU2001256166A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
AU2001234893A1 (en) Protein mapping
AU2001253197A1 (en) Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
AU4020897A (en) 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors
AU2001244167A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
ZA200301545B (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors.
AU2001242434A1 (en) Farnesyl protein transferase inhibitor combinations with vinca alkaloids
NO20032471D0 (en) farnesyl transferase
AU2435199A (en) Farnesyl transferase inhibitors
IL143408A0 (en) Tricyclic farnesyl protein transferase inhibitors
IS6358A (en) Farnesyl transferase inhibitors